

BMJ Open

Mobile phone text messaging for improving the uptake of vaccinations: a systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005130
Article Type:	Protocol
Date Submitted by the Author:	26-Feb-2014
Complete List of Authors:	Kalan, Robyn; University of Cape Town, Pediatric Medicine Wiysonge, Charles; Stellenbosch University, Centre for Evidence-Based Health Care Ramafuthole, Tshepiso; University of Cape Town, FHS Allie, Kurt; University of Cape Town, FHS Ebrahim, Fatima; University of Cape Town, FHS Engel, Mark; University of Cape Town, Medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Global health, Paediatrics, Public health
Keywords:	Vaccine coverage, vaccination, Mobile text messaging, short messaging service, SMS

SCHOLARONE™
Manuscripts

1
2
3 Mobile phone text messaging for improving the uptake of vaccinations: a systematic
4 review protocol
5
6
7

8 Robyn Kalan

9
10 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
11 Road, Observatory 7925, Cape Town, South Africa

12 Robyn.kalan@gmail.com
13

14
15 Charles S. Wiysonge

16
17 Department of Interdisciplinary Health Sciences

18 Faculty of Medicine and Health Sciences

19 Stellenbosch University

20 Tygerberg 7505, Cape Town, South Africa

21 charlesw@sun.ac.za
22
23
24
25
26
27

28 Tshepiso Ramafuthole

29
30 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
31 Cape Town, South Africa

32 rmftsh001@myuct.ac.za
33
34
35
36

37 Kurt Allie

38 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
39 Cape Town, South Africa

40 allkur003@myuct.ac.za
41
42
43
44

45 Fatima Ebrahim

46 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
47 Cape Town, South Africa

48 ebrfat010@myuct.ac.za
49
50
51
52

53 Mark Emmanuel Engel

54
55 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
56 Road, Observatory 7925, Cape Town, South Africa
57
58
59
60

1
2
3 mark.engel@uct.ac.za
4
5
6
7

8 ***Corresponding author**

9 Dr Mark Emmanuel Engel

10 Department of Medicine, University of Cape Town

11 J46-43, Old Main Building, Groote Schuur Hospital

12 Anzio Road, Observatory 7925, South Africa

13 Phone: +27 21 404 7676

14 Fax: 27 21 448 6815

15 E: mark.engel@uct.ac.za
16
17
18
19
20
21
22
23
24
25
26
27

28 **Keywords:** Vaccine coverage, vaccination, Mobile text messaging, short messaging
29 service, SMS
30
31
32
33
34
35
36
37
38
39

40 **Word Count:** 2342
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Background: Low vaccine coverage is a major public health concern, the consequences of which contribute to around 1.5 million child deaths from vaccine-preventable diseases. Thus, innovative strategies to rapidly increase coverage and recall rates for vaccinations are urgently required. Mobile text messaging (or short messaging service, SMS) has the potential to help increase vaccination coverage and therefore we propose to conduct a review of the current best evidence for the use of SMS as an intervention to promote vaccination coverage.

Methods/Design: This article describes the protocol for a systematic review of the effectiveness of SMS in improving the uptake of vaccination. Primary and secondary outcomes of interest are pre-specified. We will preferably include randomized controlled trials (RCTs). However, non-randomized studies (NRS) will be considered if there is an inadequate number of RCTs. We will search several bibliographic databases (for example PubMed, EMBASE, CINAHL, CENTRAL, Science Citation Index, Africa-Wide Information, and WHOLIS electronic databases and search sources for grey literature. Following data extraction and assessment of risk of bias, we will meta-analyze studies and conduct sub-group analyses, according to intervention subtypes. We will assess clinical heterogeneity and statistical heterogeneity. For outcomes without quantitative data, a descriptive analysis will be used.

Discussion: Our results can be used by researchers and policy-makers to help inform them of the efficacy of mobile phone text messaging interventions to promote increased vaccination coverage.

Strengths and limitations of this study

To our knowledge, this is the first systematic review protocol that will attempt to assess the impact of mobile text messaging on promoting the uptake of vaccination amongst adults, adolescents and parents or caregivers of children.

This study will help inform clinical practice and future studies on the effectiveness of media platforms.

Non-randomised studies of low-quality evidence may be this study's limitation. We will, however, conduct appropriate analyses to assess the overall robustness of the results.

Background

Vaccinations, when given at the most sensitive developmental years of childhood, help to promote comprehensive and capable immunity, enabling children to fight off certain diseases [1 2]. In addition, vaccinations are widely regarded as one of the most cost-effective public health interventions that help to reduce global child morbidity and mortality [3 4]. Low coverage of vaccinations is a major public health concern. In Africa alone, more than seven million children did not receive the full spectrum of vaccinations recommended before reaching one year of age in 2009 [5]. It is also estimated that 1.5 million children died globally from vaccine-preventable diseases where World Health Organization (WHO) pre-qualified vaccines were available [6].

The Global Vaccine Action plan (GVAP) is the most recently launched global effort by the WHO to help increase vaccination coverage. The GVAP has set a target that by 2020 vaccination coverage for populations should reach 90% national vaccination coverage and at least 80% at district levels utilizing national vaccination programmes [7]. It is guided by six principles: country ownership, shared responsibility and partnership, equity, integration, sustainability, and innovation [8]

A variety of factors impact achieving low coverage rates; challenges such as immunisation awareness, demand for immunisation, level of trust in the health system, adequate human resources, access, timeliness of vaccinations, service delivery, poor infrastructure and vaccination monitoring [3]. Vaccination coverage seems to be lower in low-income households, where limited access to health education, contributes to poor

1
2
3 health-seeking behaviour along with an inability to improve general wellbeing [1 2 9].
4
5 Uneducated parents therefore are less likely to understand the importance of
6
7 vaccinating to prevent potentially harmful diseases. In light of these obstacles to
8
9 vaccination coverage, the strategy to improve vaccination coverage needs to be
10
11 innovative as alluded to in the GVAP, well thought out and able to penetrate low income
12
13 households effectively.
14
15

16
17
18 Globally, mobile phone use is rapidly increasing, with an estimated six billion mobile
19
20 phone users worldwide at the end of 2011 [10]. In particular, mobile phone text
21
22 messaging has gained popularity among people living in low- and middle-income
23
24 countries and may be the key to penetrating hard to reach areas in the developing
25
26 world. Text messaging has proven to be a cost effective method of relaying health
27
28 information and reminders than the more traditional methods such as face to face,
29
30 phone calls, pamphlets, mail and email [5]. As immunisation usually requires multiple
31
32 consecutive monthly visits after the first vaccine dose in order to complete the schedule,
33
34 short messaging service (SMS) can be used as reminder for an upcoming visit and recall
35
36 when a visit has been missed [1]. In addition, an SMS intervention, also known as mobile
37
38 phone text messaging, can be delivered alone or bundled with other interventions [11].
39
40 Diseases that have used mobile technology successfully include HIV where a 90%
41
42 adherence was observed among text message recipients compared with a 40%
43
44 adherence in the control group [12].
45
46
47
48
49

50 We therefore propose to conduct a systematic review of the current best evidence for
51
52 the use of mobile phone text messaging to improve vaccination coverage.
53
54
55
56
57
58
59
60

Methods

The review protocol has not been registered in any prospective registers of systematic reviews.

Criteria for considering studies for this review

Type of studies

We will include randomized controlled trials (RCTs), interrupted time series and controlled before and after studies (CBA).

Types of participants

Participants will be adults, children or caregivers of those receiving vaccinations, in community-based settings.

Types of interventions

We will include interventions in which mobile phone text messages are used to promote uptake of vaccinations. The text messaging needs to be delivered to a person needing a vaccination, or in the case of an infant or child, to a caregiver. Eligible studies will be those that compared SMS to no intervention, or to other interventions for increasing vaccination coverage. If we find less than ten studies that include only SMS as the intervention, we will include studies in which mobile phone voice speaking or voice messaging are interventions; studies in which the use of a beeper or pager is the intervention; studies in which the use of multimedia messaging service is the

1
2
3 intervention; and studies in which text messages are bundled with other interventions.

4
5 In such circumstances, we will stratify the analysis by type of intervention.

6
7
8
9 ***Types of outcome measures***

10 Results must include quantitative data for outcomes measured.

11
12
13
14 ***Primary outcomes:***

15
16
17 The primary outcome is vaccination coverage, irrespective of disease.

18
19
20
21
22 ***Secondary outcomes:***

23
24 Secondary outcomes are the recall rate in persons who had previously missed their
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
vaccinations.

31
32 **Search methods for identification of studies**

33
34 A comprehensive and exhaustive search will be performed by RK with the help of the
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
University of Cape Town librarian, to identify all relevant studies available by 30 June
2013, regardless of language or publication status. We will search both peer-reviewed
journal articles and grey literature (unpublished, internal or non-reviewed papers and
reports).

48
49
50
51
52
53
54
55
56
57
58
59
60
Database

51
52
53
54
55
56
57
58
59
60
We will search the following electronic databases: PubMed; EMBASE; Cochrane Central
Register of Controlled Trials (CENTRAL); ISI Web of Science (Science Citation Index);
Africa-Wide Information, Cumulative Index of Nursing and Allied Health (CINAHL), and
WHO library databases (WHOLIS). We will use both text words and medical subject

1
2
3 heading (MeSH) terms; for example vaccination*, immunization*, immunisation*,
4
5 "Immunization"(MeSH), "Vaccination"(MeSH), "Immunization, Secondary"(MeSH) OR
6
7 "Immunization Programs"(MeSH), "Immunization Schedule"(MeSH), "Mass
8
9 Vaccination"(MeSH), mobile phone, text messaging, text*, SMS, reminder*, recall,
10
11 telemedicine, mHealth, and eHealth. These terms will be used in varying combinations.
12
13 The literature search strategy will be adapted to suit each database. Table 1 shows the
14
15 main search strategy we will use.
16
17
18
19

20 21 ***Conference proceedings***

22
23 We will search the following conference proceedings for relevant abstracts: Vaccine and
24
25 International Society for Vaccines Congress, International African Vaccinology Conference,
26
27 Annual Vaccines Congress, Annual Conference on Vaccine Research, World Congress on
28
29 Pediatric Infectious Diseases, International Pediatric Association Conference, National
30
31 Immunization Conference, and the Annual Infectious Diseases in Children Symposium.
32
33
34
35
36

37 38 ***Searching other sources***

39
40 For ongoing studies, we will search the WHO International Clinical trials Registry
41
42 Platform, Clinicaltrials.gov, Pan African Clinical Trials Registry (PACTR), and contact
43
44 individual researchers working in the field as well as the following organizations: WHO,
45
46 Global Alliance for Vaccines and Immunisation, Centers for Disease Control and
47
48 Prevention, and mHealth Alliance. We will also search the website of mHealth Alliance
49
50 and mHealth in the Low Resource Settings resources database [20] for eligible studies.
51
52
53
54
55
56
57
58
59
60

Reference lists

We will obtain reference lists of relevant studies identified and the full-text articles reviewed for inclusion in the review will be checked for additional information.

Data collection and analysis

The methods for data collection and analysis will be based on the Cochrane Handbook of Systematic Reviews for Interventions [13].

Selection of studies

We will construct a screening guide to ensure that the inclusion criteria are adhered to and consistently applied by all review authors. Two review authors (RK and ME), working independently, will screen the titles and abstracts of all studies identified through the literature searches for eligibility. RK will obtain the full text of studies deemed potentially eligible. The two authors (RK and ME) will independently assess the full text of each article for eligibility, and compare their results and resolve discrepancies by discussion and consensus, consulting a third author (CW) to resolve any persistent disagreements. For all studies excluded by the assessors we will describe the reasons for exclusion.

Data extraction and management

References will be managed using Thomson ISI Research-Soft Endnote 9.0 [14]. Two authors will independently extract descriptive and outcome data for each included article using a standardized data collection form, resolving any discrepancies by

1
2
3 discussion and consensus; failing which, a third author (CW) will arbitrate. RK will
4
5 enter the final data into the Cochrane Collaboration Review Manager Version 5.1
6
7 statistical software (<http://ims.cochrane.org/RevMan>). CW will crosscheck the data
8
9 entered to ensure that there are no data entry errors.
10

11 12 13 14 ***Assessment of risk of bias in included studies***

15
16 Two authors will independently assess the risk of bias in the included studies. Separate
17
18 criteria will be used to assess RCTs and non-randomized studies. The criteria used to
19
20 assess the risk of bias of in RCTs will be random sequence generation; allocation
21
22 concealment; blinding of participants, study personnel; blinding of outcome assessors;
23
24 incomplete outcome data; selective outcome reporting; other sources of bias, and
25
26 overall risk of bias, in accordance with the methods used by the Cochrane Collaboration
27
28 [13] as well as the Cochrane Consumers and Communication Review Group [15]. The
29
30 criteria used for risk of bias assessment for non-randomized studies will include
31
32 selection bias (with regard to comparability of groups, confounding and adjustment);
33
34 performance bias (in terms of the fidelity of the interventions, and quality of the
35
36 information regarding who received which interventions, including blinding of study
37
38 subjects and healthcare providers); detection bias (regarding unbiased and correct
39
40 assessment of outcomes, including blinding of assessors); attrition bias (with regard to
41
42 completeness of sample, follow-up and data); and reporting bias (with regard to
43
44 publication biases and selective reporting of results) [13]. Studies will be scored as
45
46 having low, high or unclear risk of bias. The two authors will resolve disagreements in
47
48 the assessment of risk of bias by discussion and consensus, consulting a third author to
49
50 resolve any persistent disagreements.
51
52
53
54
55
56
57
58
59
60

Measures of treatment effect

Data analysis will be conducted using the Cochrane Collaboration Review Manager Version 5.1 statistical software (<http://ims.cochrane.org/RevMan>). The outcomes of interest will be either dichotomous or continuous. We will calculate risk ratios and their corresponding 95% confidence intervals and P-values for dichotomous outcomes, and mean differences for continuous outcomes.

Dealing with missing data

In cases of missing or incomplete information presented in the included studies, we shall contact authors for further information.

Data synthesis, assessment/investigation of heterogeneity

We will assess clinical heterogeneity by examining types of participants, interventions, and outcomes in each study. We will pool data only from studies judged to be clinically homogenous. Statistical heterogeneity in each meta-analysis will be assessed using the chi-square test and quantified using the I-squared statistic. If studies are sufficiently homogenous (in terms of study populations, interventions, and outcomes), then we will pool the data across studies and estimate summary effect sizes using a fixed-effects model. Otherwise, we will use the random-effects model. We will perform subgroup analyses by intervention subtypes: long versus short messages; daily versus weekly messages; short weekly messages versus long weekly messages; short daily messages versus long daily messages; and two-way interactive communication versus one-way communication [16] [12 17]. We will also stratify analysis by study design (randomized controlled separate from non-randomized studies) and intervention type (multiple

1
2
3 interventions involving text messaging separate from text messaging alone). Finally, we
4
5 will use the grading of recommendations assessment, development, and evaluation
6
7 (GRADE) approach [18] to assess the quality of evidence for the effectiveness of the SMS
8
9 intervention. This method results in an assessment of the quality of the body of evidence
10
11 as high, moderate, low, or very low. Evidence is considered of high quality if 'further
12
13 research is very unlikely to change our confidence in the estimate of effect'; and
14
15 moderate quality if 'further research is likely to have an important impact on our
16
17 confidence in the estimate of effect and may change the estimate'. Low quality evidence
18
19 implies that 'further research is very likely to have an important impact on our
20
21 confidence in the estimate of effect and is likely to change the estimate', and very low
22
23 quality that 'we have very little confidence in the effect estimate'.
24
25
26
27
28
29
30

31 ***Sensitivity analyses***

32
33 Several sensitivity analyses will be performed: first to determine whether the study
34
35 design (RCT versus nonrandomized study) could influence the results of the meta-
36
37 analysis; second, to evaluate whether the model of the statistical method (random-
38
39 effects vs fixed-effects model) could change the results, and third, to determine the
40
41 impact of excluding studies with a high risk bias on the results, with emphasis on
42
43 allocation concealment, blinded outcome assessment, and losses to follow-up (with a cut
44
45 off of 25% loss to follow-up).
46
47
48
49
50

51 **Presenting and reporting of results**

52
53
54 Findings in our systematic review will be presented in several ways. Flow diagrams will
55
56 be used to summarise the study selection process. Funnel plots will be used to assess
57
58
59
60

1
2
3 publication bias if we identify 10 or more eligible studies. The kappa statistic [19] will
4
5 be used to assess agreements between the full-text screening, data extraction and risk of
6
7 bias assessment by the two authors (RK and ME). GRADE summary of tables of findings,
8
9 risk of bias tables or graphs, and forest plots will also be used where appropriate. The
10
11 reporting of outcomes without quantitative data will be descriptive. Lastly, we will
12
13 provide a list of excluded studies with reasons for exclusion.
14
15
16
17
18

19 **Ethics**

20
21
22 Systematic reviews draw on publicly available data and do not directly involve human
23
24 subjects, and therefore do not require formal ethical review [20]. The study protocol
25
26 will be reviewed by supervisors with expertise in methodology (systematic review) and
27
28 submitted to the University of Cape Town Departmental Research Committee for
29
30 approval.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Expected significance of the study

The findings of this systematic review will have implications for policy, practice and research. We will discuss the relevance of our findings to childhood immunisation programmes in Africa in the decade of vaccines with emphasis on applicability, effects on equity, cost implications, and monitoring and evaluation.

Our systematic review will provide evidence of whether policy-makers can adopt mobile phone text messaging alone or in combination with other interventions in efforts to improve uptake of vaccines in national immunisation programmes. It will also inform clinic or hospital managers of how best to use the intervention to improve vaccination coverage. The systematic review may also identify specific considerations that would need to be taken into account for future studies, such as study location, content and timing of messages, whether or not parents or caregivers replied to text messages, how text messages were sent (automated versus manual), indicators for immunisation programmes, variety of text messages sent (inclusion of jokes or lifestyle tips), duration of the study, whether or not participants were provided with the mobile handsets, and sample size [21].

Abbreviations

WHO: World Health Organization; GVAP: Global Vaccine Action plan; SMS: Short messaging service; RCT: Randomized Controlled Trials; CBA: Controlled Before and After study; MeSH: medical subject heading;

Contributorship Statement

RK and ME drafted the protocol.

CW conceived of the review.

All authors developed the design of the protocol and will be involved in data acquisition.

All authors have given their approval for publication of the protocol

Competing Interests

None

References

1. Garde M. Inequalities in child survival: Looking at wealth and other socio-economic disparities in developing countries.
http://www.savethechildren.org.uk/sites/default/files/docs/Final_draft_inequalities_of_child_survival_10_August_formatted_2_1.pdf [Accessed August 5th 2012] 2010
2. Multiple Authors. Vaccines & Preventable Diseases. National Center for Immunization and Respiratory Disease. <http://www.cdc.gov/vaccines/vpd-vac/default.htm> 2009
3. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. *PLoS medicine* 2013;**10**(3):e1001405 doi: 10.1371/journal.pmed.1001405 [published Online First: Epub Date]].
4. Bloom DE. The value of vaccination. *Advances in experimental medicine and biology* 2011;**697**:1-8 doi: 10.1007/978-1-4419-7185-2_1 [published Online First: Epub Date]].
5. Stockwell MS, Kharbanda EO, Martinez RA, et al. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations. *American journal of public health* 2012;**102**(2):e15-21 doi: 10.2105/AJPH.2011.300331 [published Online First: Epub Date]].
6. World Health Organisation and UNICEF: Global Immunization Data. World Health Organisation and UNICEF: Global Immunization Data.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
7. WHO Global Vaccination Action Plan.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
8. Decade of Vaccines (DoV) Collaboration: Draft global vaccine action plan.
[<http://www.dovcollaboration.org/action-plan/>] Accessed 10 June 2013.

- 1
2
3 9. Kaewkungwal J, Singhasivanon P, Khamsiriwatchara A, et al. Application of smart phone in "Better
4
5 Border Healthcare Program": a module for mother and child care. BMC medical informatics
6
7 and decision making 2010;**10**:69 doi: 10.1186/1472-6947-10-69[published Online First: Epub
8
9 Date]].
10
- 11
12 10. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a
13
14 meta-analysis. Medical care 1998;**36**(8):1138-61
15
- 16
17 11. Mohammed S, Siddiqi O, Ali O, et al. User engagement with and attitudes towards an interactive
18
19 SMS reminder system for patients with tuberculosis. J Telemed Telecare 2012;**18**(7):404-8
20
21 doi: 10.1258/jtt.2012.120311[published Online First: Epub Date]].
22
- 23
24 12. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve
25
26 adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled
27
28 trial of text message reminders. AIDS 2011;**25**(6):825-34 doi:
29
30 10.1097/QAD.0b013e32834380c1[published Online First: Epub Date]].
31
- 32
33 13. Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions*.
34
35 *Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from*
36
37 <http://www.cochrane-handbook.org>, 2009.
38
- 39
40 14. Thomson. <http://www.endnote.com>. ISI Research-Soft Endnote 90
41
- 42
43 15. Ryan R HS, Pictor M, McKenzie J; Cochrane Consumers and Communication Review Group.
44
45 Study Quality Guide.
46
47 http://ccrgcochraneorg/sites/ccrgcochraneorg/files/uploads/StudyQualityGuide_Ma
48
49 y2011pdf (accessed 01 February 2013) 2011
50
- 51
52 16. Horvath T, Azman H, Kennedy GE, et al. Mobile phone text messaging for promoting adherence
53
54 to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev
55
56 2012;**3**:CD009756 doi: 10.1002/14651858.CD009756[published Online First: Epub Date]].
57
58
59
60

- 1
2
3 17. Thirumurthy H, Lester RT. M-health for health behaviour change in resource-limited settings:
4 applications to HIV care and beyond. Bulletin of the World Health Organization
5 2012;**90**(5):390-2 doi: 10.2471/BLT.11.099317[published Online First: Epub Date]].
6
7
8
9 18. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of
10 evidence. J Clin Epidemiol 2011;**64**(4):401-6 doi: 10.1016/j.jclinepi.2010.07.015[published
11 Online First: Epub Date]].
12
13
14
15 19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics
16 1977;**33**(1):159-74
17
18
19
20 20. Emanuel EJ, Wendler D, Killen J, et al. What makes clinical research in developing countries
21 ethical? The benchmarks of ethical research. J Infect Dis 2004;**189**(5):930-7 doi:
22 10.1086/381709[published Online First: Epub Date]].
23
24
25
26
27 21. Karanja S, Mbuagbaw L, Ritvo P, et al. A workshop report on HIV mHealth synergy and strategy
28 meeting to review emerging evidence-based mHealth interventions and develop a
29 framework for scale-up of these interventions. The Pan African medical journal 2011;**10**:37
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. PubMed search strategy, modified as needed for use in other databases

Search	PubMed
#1	(immunization[Mesh]) OR (immunis* OR immuniz* OR vaccin*)
#2	(adolescents OR children OR teenagers)
#3	"SMS" OR cellphone OR "mobile phone" OR "text messaging" OR "short message service" OR "text reminder"
#4	#1 AND #2
#5	#3 AND #4

MeSH, medical subject heading

BMJ Open

Mobile phone text messaging for improving the uptake of vaccinations: a systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005130.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Jun-2014
Complete List of Authors:	Kalan, Robyn; University of Cape Town, Pediatric Medicine Wiysonge, Charles; Stellenbosch University, Centre for Evidence-Based Health Care Ramafuthole, Tshepiso; University of Cape Town, FHS Allie, Kurt; University of Cape Town, FHS Ebrahim, Fatima; University of Cape Town, FHS Engel, Mark; University of Cape Town, Medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Global health, Paediatrics, Public health
Keywords:	Vaccine coverage, vaccination, Mobile text messaging, short messaging service, SMS

SCHOLARONE™
Manuscripts

1
2
3 **Mobile phone text messaging for improving the uptake of vaccinations: a**
4 **systematic review protocol**
5
6
7

8 Robyn Kalan

9
10 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
11 Road, Observatory 7925, Cape Town, South Africa

12 Robyn.kalan@gmail.com
13

14
15 Charles S. Wiysonge

16
17 Department of Interdisciplinary Health Sciences, Faculty of Medicine and Health
18 Sciences, Stellenbosch University, Tygerberg 7505, Cape Town, South Africa

19 charlesw@sun.ac.za
20
21

22
23 Tshepiso Ramafuthole

24
25 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
26 Cape Town, South Africa

27 rmftsh001@myuct.ac.za
28
29

30
31 Kurt Allie

32
33 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
34 Cape Town, South Africa

35 allkur003@myuct.ac.za
36
37

38
39 Fatima Ebrahim

40
41 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
42 Cape Town, South Africa

43 ebrfat010@myuct.ac.za
44
45

46
47 Mark Emmanuel Engel

48
49 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
50 Road, Observatory 7925, Cape Town, South Africa

51 mark.engel@uct.ac.za
52
53
54
55
56
57
58
59
60

***Corresponding author**

Dr Mark Emmanuel Engel

Department of Medicine, University of Cape Town

J46-43, Old Main Building, Groote Schuur Hospital

Anzio Road, Observatory 7925, South Africa

Phone: +27 21 404 7676

Fax: 27 21 448 6815

E: mark.engel@uct.ac.za

Keywords: Vaccine coverage, vaccination, Mobile text messaging, short messaging service, SMS

Word Count: 2424

ABSTRACT

Introduction: Low vaccine coverage is a major public health concern, the consequences of which contribute to around 1.5 million child deaths from vaccine-preventable diseases. Thus, innovative strategies to rapidly increase coverage and recall rates for vaccinations are urgently required. Mobile text messaging (or short messaging service, SMS) has the potential to help increase vaccination coverage and therefore we propose to conduct a review of the current best evidence for the use of SMS as an intervention to promote vaccination coverage.

Methods and Analysis: This article describes the protocol for a systematic review of the effectiveness of SMS in improving the uptake of vaccination. Primary and secondary outcomes of interest are pre-specified. We will preferably include randomized controlled trials (RCTs). However, non-randomized studies (NRS) will be considered if there is an inadequate number of RCTs. We will search several bibliographic databases (for example PubMed, EMBASE, CINAHL, CENTRAL, Science Citation Index, Africa-Wide Information, and WHOLIS electronic databases and search sources for grey literature. Following data extraction and assessment of risk of bias, we will meta-analyze studies and conduct sub-group analyses, according to intervention subtypes. We will assess clinical heterogeneity and statistical heterogeneity. For outcomes without quantitative data, a descriptive analysis will be used. This review protocol is registered in the PROSPERO International Prospective Register of systematic reviews, registration number 2014:CRD42014007531

1
2
3 **Ethics and dissemination:** Ethics is not required for this study, given that this is a
4
5
6 protocol for a systematic review, which uses published data. This findings of this study
7
8 will be disseminated through peer-reviewed publications and conference presentations.
9
10 We anticipate that the results could be used by researchers and policy-makers to help
11
12 inform them of the efficacy of mobile phone text messaging interventions to promote
13
14 increased vaccination coverage.
15
16
17
18
19
20

21 **Strengths and limitations of this study**

- 24 • To our knowledge, this is the first systematic review protocol that will attempt to
25 assess the impact of mobile text messaging on promoting the uptake of
26 vaccination amongst adults, adolescents and parents or caregivers of children.
27
28
- 29 • This study will help inform clinical practice and future studies on the
30 effectiveness of media platforms.
31
32
- 33 • Non-randomised studies of low-quality evidence may be this study's limitation.
34
35 We will, however, conduct appropriate analyses to assess the overall robustness
36 of the results.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Vaccinations, when given at the most sensitive developmental years of childhood, help to promote comprehensive and capable immunity, enabling children to fight off certain diseases [1 2]. In addition, vaccinations are widely regarded as one of the most cost-effective public health interventions that help to reduce global child morbidity and mortality [3 4]. Low coverage of vaccinations is a major public health concern. In Africa alone, more than seven million children did not receive the full spectrum of vaccinations recommended before reaching one year of age in 2009 [5]. It is also estimated that 1.5 million children died globally from vaccine-preventable diseases where World Health Organization (WHO) pre-qualified vaccines were available [6].

The Global Vaccine Action plan (GVAP) is the most recently launched global effort by the WHO to help increase vaccination coverage. The GVAP has set a target that by 2020 vaccination coverage for populations should reach 90% national vaccination coverage and at least 80% at district levels utilizing national vaccination programmes [7]. It is guided by six principles: country ownership, shared responsibility and partnership, equity, integration, sustainability, and innovation [8]

A variety of factors impact achieving low coverage rates; challenges such as immunisation awareness, demand for immunisation, level of trust in the health system, adequate human resources, access, timeliness of vaccinations, service delivery, poor infrastructure and vaccination monitoring [4]. Vaccination coverage seems to be lower in low-income households, where limited access to health education, contributes to poor

1
2
3 health-seeking behaviour along with an inability to improve general wellbeing [1 2 9].
4
5 Uneducated parents therefore are less likely to understand the importance of
6
7 vaccinating to prevent potentially harmful diseases. In light of these obstacles to
8
9 vaccination coverage, the strategy to improve vaccination coverage needs to be
10
11 innovative as alluded to in the GVAP, well thought out and able to penetrate low income
12
13 households effectively.
14
15

16
17
18 Globally, mobile phone use is rapidly increasing, with an estimated six billion mobile
19
20 phone users worldwide at the end of 2011 [10]. In particular, mobile phone text
21
22 messaging has gained popularity among people living in low- and middle-income
23
24 countries and may be the key to penetrating hard to reach areas in the developing
25
26 world. Text messaging has proven to be a cost effective method of relaying health
27
28 information and reminders than the more traditional methods such as face-to-face,
29
30 phone calls, pamphlets, mail and email [5]. As immunisation usually requires multiple
31
32 consecutive monthly visits after the first vaccine dose in order to complete the schedule,
33
34 short messaging service (SMS) can be used as reminder for an upcoming visit and recall
35
36 when a visit has been missed [1]. In addition, an SMS intervention, also known as mobile
37
38 phone text messaging, can be delivered alone or bundled with other interventions [11].
39
40 Diseases that have used mobile technology successfully include HIV where a 90%
41
42 adherence was observed among text message recipients compared with a 40%
43
44 adherence in the control group [12]. We therefore propose to conduct a systematic
45
46 review of the current best evidence for the use of mobile phone text messaging to
47
48 improve vaccination coverage.
49
50
51
52
53
54
55
56
57
58
59
60

Methods

This review protocol has been published in the PROSPERO International Prospective Register of systematic reviews (<http://www.crd.york.ac.uk/PROSPERO>), registration number 2014:CRD42014007531.

Criteria for considering studies for this review

Type of studies

We will include randomized controlled trials (RCTs), interrupted time series and controlled before and after studies (CBA).

Types of participants

Participants will be caregivers of infants or children, adolescents and adults including pregnant women drawn from any setting, community-based or otherwise.

Types of interventions

We will include interventions in which mobile phone text messages serve as a reminder to be vaccinated, as educational information or, as information regarding vaccine availability at the clinic in an attempt to promote uptake of vaccinations. Vaccinations could include routine infant immunisations, those against human papilloma virus, influenza, meningococcal (MCV4) or tetanus/diphtheria/acellular pertussis (Tdap). Eligible studies will be those that compared SMS to no intervention, or to other interventions for increasing vaccination coverage. If we find less than ten studies that include only SMS as the intervention, we will include studies in which mobile phone voice speaking or voice messaging are

1
2
3 interventions; studies in which the use of a beeper or pager is the intervention; studies
4
5 in which the use of multimedia messaging service is the intervention; and studies in
6
7 which text messages are bundled with other interventions. In such circumstances, we
8
9 will stratify the analysis by type of intervention.
10

11 12 13 ***Types of outcome measures***

14
15 Results must include quantitative data for outcomes measured.
16

17 18 19 ***Primary outcomes:***

20
21 The primary outcome is vaccination coverage, irrespective of disease. We will use the
22
23 definition of vaccine coverage as stipulated by the respective authors.
24
25

26 27 28 29 ***Secondary outcomes:***

30
31 Secondary outcomes are the recall rate in persons who had previously missed their
32
33 vaccinations, scheduled appointments for vaccination or completeness of vaccination
34
35 records.
36
37

38 39 40 **Search methods for identification of studies**

41
42 A comprehensive and exhaustive search of databases and conference proceedings will be
43
44 performed by RK with the help of the University of Cape Town librarian, to identify all
45
46 relevant studies available by 30 June 2014, regardless of language or publication status.
47
48 We will search both peer-reviewed journal articles and grey literature (unpublished,
49
50 internal or non-reviewed papers and reports).
51
52
53
54
55
56
57
58
59
60

Database

We will search the following electronic databases: PubMed; EMBASE; Cochrane Central Register of Controlled Trials (CENTRAL); ISI Web of Science (Science Citation Index); Africa-Wide Information, Cumulative Index of Nursing and Allied Health (CINAHL), and WHO library databases (WHOLIS). We will use both text words and medical subject heading (MeSH) terms; for example vaccination*, immunization*, immunisation*, "Immunization"(MeSH), "Vaccination"(MeSH), "Immunization, Secondary"(MeSH) OR "Immunization Programs"(MeSH), "Immunization Schedule"(MeSH), "Mass Vaccination"(MeSH), mobile phone, text messaging, text*, SMS, reminder*, recall, telemedicine, mHealth, and eHealth. These terms will be used in varying combinations. The literature search strategy will be adapted to suit each database. Table 1 shows the main search strategy we will use.

Conference proceedings

We will search the following conference proceedings for relevant abstracts: Vaccine and International Society for Vaccines Congress, International African Vaccinology Conference, Annual Vaccines Congress, Annual Conference on Vaccine Research, World Congress on Pediatric Infectious Diseases, International Pediatric Association Conference, National Immunization Conference, and the Annual Infectious Diseases in Children Symposium.

Searching other sources

For ongoing studies, we will search the WHO International Clinical trials Registry Platform, Clinicaltrials.gov, Pan African Clinical Trials Registry (PACTR), and contact individual researchers working in the field as well as the following organizations: WHO,

1
2
3 Global Alliance for Vaccines and Immunisation, Centers for Disease Control and
4
5 Prevention, and mHealth Alliance. We will also search the website of mHealth Alliance
6
7 and mHealth in the Low Resource Settings resources database for eligible studies.
8
9

10 11 12 ***Reference lists***

13
14
15 We will obtain reference lists of relevant studies identified and the full-text articles
16
17 reviewed for inclusion in the review will be checked for additional information.
18
19

20 21 22 **Data collection and analysis**

23
24
25 The methods for data collection and analysis will be based on the Cochrane Handbook of
26
27 Systematic Reviews for Interventions [13].
28
29

30 31 32 ***Selection of studies for inclusion***

33
34
35 We will construct a screening guide to ensure that the inclusion criteria are adhered to
36
37 and consistently applied by all review authors. Two review authors (RK and ME),
38
39 working independently, will screen the titles and abstracts of all studies identified
40
41 through the literature searches for eligibility. RK will obtain the full text of studies
42
43 deemed potentially eligible. The two authors (RK and ME) will independently assess the
44
45 full text of each article for eligibility, and compare their results and resolve
46
47 discrepancies by discussion and consensus, consulting a third author (CW) to resolve
48
49 any persistent disagreements. For all studies excluded by the assessors we will describe
50
51 the reasons for exclusion.
52
53
54
55
56
57
58
59
60

Assessment of risk of bias in included studies

Two authors will independently assess the risk of bias in the included studies. Separate criteria will be used to assess RCTs and non-randomized studies. The criteria used to assess the risk of bias of in RCTs will be random sequence generation; allocation concealment; blinding of participants, study personnel; blinding of outcome assessors; incomplete outcome data; selective outcome reporting; other sources of bias, and overall risk of bias, in accordance with the methods used by the Cochrane Collaboration [13] as well as the Cochrane Consumers and Communication Review Group[14]. The criteria used for risk of bias assessment for non-randomized studies will include selection bias (with regard to comparability of groups, confounding and adjustment); performance bias (in terms of the fidelity of the interventions, and quality of the information regarding who received which interventions, including blinding of study subjects and healthcare providers); detection bias (regarding unbiased and correct assessment of outcomes, including blinding of assessors); attrition bias (with regard to completeness of sample, follow-up and data); and reporting bias (with regard to publication biases and selective reporting of results) [13]. Studies will be scored as having low, high or unclear risk of bias. The two authors will resolve disagreements in the assessment of risk of bias by discussion and consensus, consulting a third author to resolve any persistent disagreements.

Data extraction and management

References will be managed using Thomson ISI Research-Soft Endnote 9.0 [15]. Two authors will independently extract descriptive and outcome data for each included article using a standardized data collection form, resolving any discrepancies by discussion and consensus; failing which, a third author (CW) will arbitrate. RK will

1
2
3 enter the final data into the Cochrane Collaboration Review Manager Version 5.1
4 statistical software (<http://ims.cochrane.org/RevMan>). CW will crosscheck the data
5
6 entered to ensure that there are no data entry errors.
7
8
9

10 11 12 ***Data synthesis including assessment of heterogeneity*** 13

14
15 Data analysis will be conducted using the Cochrane Collaboration Review Manager
16 Version 5.1 statistical software (<http://ims.cochrane.org/RevMan>). The outcomes of
17 interest will be either dichotomous or continuous. We will calculate risk ratios and their
18 corresponding 95% confidence intervals and P-values for dichotomous outcomes, and
19 mean differences and standard deviations for continuous outcomes. Where outcomes are
20 measured using different scales, we will report standardised mean differences (SMD) [16]. In
21 cases of missing or incomplete information presented in the included studies, we shall
22 contact authors for further information.
23
24
25
26
27
28
29
30
31
32

33
34
35 We will assess clinical heterogeneity by examining types of participants, interventions,
36 and outcomes in each study. We will pool data only from studies judged to be clinically
37 homogenous. Statistical heterogeneity in each meta-analysis will be assessed using the
38 chi-square test and quantified using the I-squared statistic [17] . If studies are
39 sufficiently homogenous (in terms of study populations, interventions, and outcomes),
40 then we will pool the data across studies and estimate summary effect sizes using a
41 fixed-effects model. Otherwise, we will use the random-effects model. Should
42 heterogeneity remain significant, we will discuss the findings as a narrative summary.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We will perform subgroup analyses by intervention subtypes: long versus short
4 messages; daily versus weekly messages; short weekly messages versus long weekly
5 messages; short daily messages versus long daily messages; and two-way interactive
6 communication versus one-way communication [12 18 19]. We will also stratify analysis
7 by study design (randomized controlled separate from non-randomized studies) and
8 intervention type (multiple interventions involving text messaging separate from text
9 messaging alone). We will also conduct a subgroup comparison of self-reported vaccination
10 completion versus verified clinic records as well as according to age categories and country
11 setting.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 Finally, we will use the grading of recommendations assessment, development, and
26 evaluation (GRADE) approach [20] to assess the quality of evidence for the effectiveness
27 of the SMS intervention. This method results in an assessment of the quality of the body
28 of evidence as high, moderate, low, or very low. Evidence is considered of high quality if
29 'further research is very unlikely to change our confidence in the estimate of effect'; and
30 moderate quality if 'further research is likely to have an important impact on our
31 confidence in the estimate of effect and may change the estimate'. Low quality evidence
32 implies that 'further research is very likely to have an important impact on our
33 confidence in the estimate of effect and is likely to change the estimate', and very low
34 quality that 'we have very little confidence in the effect estimate'.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 ***Sensitivity analyses***

52
53
54 Several sensitivity analyses will be performed: first to determine whether the study
55 design (RCT versus nonrandomized study) could influence the results of the meta-
56
57
58
59
60

1
2
3 analysis; second, to evaluate whether the model of the statistical method (random-
4 effects vs fixed-effects model) could change the results, and third, to determine the
5 impact of excluding studies with a high risk bias on the results, with emphasis on
6 allocation concealment, blinded outcome assessment, and losses to follow-up (with a cut
7 off of 25% loss to follow-up).
8
9
10
11
12

13 14 15 16 **Reporting of this review** 17

18
19 Findings in our systematic review will be presented in several ways. Flow diagrams will
20 be used to summarise the study selection process. Funnel plots will be used to assess
21 publication bias if we identify 10 or more eligible studies. The kappa statistic [21] will
22 be used to assess agreements between the full-text screening, data extraction and risk of
23 bias assessment by the two authors (RK and ME). GRADE summary of tables of findings,
24 risk of bias tables or graphs, and forest plots will also be used where appropriate. The
25 reporting of outcomes without quantitative data will be descriptive. Lastly, we will
26 provide a list of excluded studies with reasons for exclusion.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Ethics and dissemination** 41

42
43 Systematic reviews draw on publicly available data and do not directly involve human
44 subjects, and therefore do not require formal ethical review [22]. The study protocol
45 will be reviewed by supervisors with expertise in methodology (systematic review) and
46 submitted to the University of Cape Town Departmental Research Committee for
47 approval.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The findings of this systematic review will have implications for policy, practice and
4
5 research. We will discuss the relevance of our findings to childhood immunisation
6
7 programmes in Africa in the decade of vaccines with emphasis on applicability, effects
8
9 on equity, cost implications, and monitoring and evaluation. Our systematic review will
10
11 provide evidence of whether policy-makers can adopt mobile phone text messaging
12
13 alone or in combination with other interventions in efforts to improve uptake of
14
15 vaccines in national immunisation programmes. It will also inform clinic or hospital
16
17 managers of how best to use the intervention to improve vaccination coverage. The
18
19 systematic review may also identify specific considerations that would need to be taken
20
21 into account for future studies, such as study location, content and timing of messages,
22
23 whether or not parents or caregivers replied to text messages, how text messages were
24
25 sent (automated versus manual), indicators for immunisation programmes, variety of
26
27 text messages sent (inclusion of jokes or lifestyle tips), duration of the study, whether or
28
29 not participants were provided with the mobile handsets, and sample size [23].
30
31
32
33
34
35
36
37

38 **Abbreviations**

39
40 WHO: World Health Organization; GVAP: Global Vaccine Action plan; SMS: Short
41
42 messaging service; RCT: Randomized Controlled Trials; CBA: Controlled Before and
43
44 After study; MeSH: medical subject heading;
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

The authors would like to acknowledge the critical input and support of the Evidence-Based Medicine Research Support Unit, Faculty of Health Sciences, University of Cape Town.

Contributionship statement

Robyn Kalan, BSc (Hons) Nursing is a research fellow. Tshepiso Ramafuthole, Kurt Allie and Fatima Ebrahim are MBChB students. Mark Engel, MPH, PhD and Charles Wiysonge, MD, PhD are senior researchers.

CW, TR, KA, and FE conceived of the review. All authors developed the design of the protocol and will be involved in data acquisition. RK undertook the drafting of the manuscript. RK and ME will analyze the data and participate in the interpretation of the results. All authors have given their approval for publication.

Competing interests

The authors declare that they have no competing interests.

Funding

We did not receive any dedicated funding for this manuscript.

References

1. Garde M. Inequalities in child survival: Looking at wealth and other socio-economic disparities in developing countries.
http://www.savethechildren.org.uk/sites/default/files/docs/Final_draft_inequalities_of_child_survival_10_August_formatted_2_1.pdf [Accessed August 5th 2012] 2010
2. Multiple Authors. Vaccines & Preventable Diseases. National Center for Immunization and Respiratory Disease. <http://www.cdc.gov/vaccines/vpd-vac/default.htm> 2009
3. Bloom DE. The value of vaccination. *Advances in experimental medicine and biology* 2011;**697**:1-8 doi: 10.1007/978-1-4419-7185-2_1 [published Online First: Epub Date]].
4. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. *PLoS medicine* 2013;**10**(3):e1001405 doi: 10.1371/journal.pmed.1001405 [published Online First: Epub Date]].
5. Stockwell MS, Kharbanda EO, Martinez RA, et al. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations. *American journal of public health* 2012;**102**(2):e15-21 doi: 10.2105/AJPH.2011.300331 [published Online First: Epub Date]].
6. World Health Organisation and UNICEF: Global Immunization Data. World Health Organisation and UNICEF: Global Immunization Data.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
7. WHO Global Vaccination Action Plan.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
8. Decade of Vaccines (DoV) Collaboration: Draft global vaccine action plan.
[<http://www.dovcollaboration.org/action-plan/>] Accessed 10 June 2013
9. Kaewkungwal J, Singhasivanon P, Khamsiriwatchara A, et al. Application of smart phone in "Better Border Healthcare Program": a module for mother and child care. *BMC medical informatics and decision making* 2010;**10**:69 doi: 10.1186/1472-6947-10-69 [published Online First: Epub Date]].
10. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. *Medical care* 1998;**36**(8):1138-61
11. Mohammed S, Siddiqi O, Ali O, et al. User engagement with and attitudes towards an interactive SMS reminder system for patients with tuberculosis. *J Telemed Telecare* 2012;**18**(7):404-8 doi: 10.1258/jtt.2012.120311 [published Online First: Epub Date]].
12. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS* 2011;**25**(6):825-34 doi: 10.1097/QAD.0b013e32834380c1 [published Online First: Epub Date]].
13. Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from <http://www.cochrane-handbook.org>, 2009.*
14. Ryan R HS, Prictor M, McKenzie J;. Cochrane Consumers and Communication Review Group. Study Quality Guide.
http://ccrg.cochrane.org/sites/ccrg.cochrane.org/files/uploads/StudyQualityGuide_May2011.pdf (accessed 01 February 2013) 2011
15. Thomson. <http://www.endnote.com>. ISI Research-Soft Endnote 90
16. Borenstein M. *Introduction to meta-analysis*. Chichester, U.K.: John Wiley & Sons, 2009.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;**21**(11):1539-58
18. Horvath T, Azman H, Kennedy GE, et al. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. *Cochrane Database*

- 1
2
3 Syst Rev 2012;**3**:CD009756 doi: 10.1002/14651858.CD009756[published Online First:
4 Epub Date]].
- 5 19. Thirumurthy H, Lester RT. M-health for health behaviour change in resource-limited
6 settings: applications to HIV care and beyond. Bulletin of the World Health Organization
7 2012;**90**(5):390-2 doi: 10.2471/BLT.11.099317[published Online First: Epub Date]].
- 8 20. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of
9 evidence. J Clin Epidemiol 2011;**64**(4):401-6 doi:
10 10.1016/j.jclinepi.2010.07.015[published Online First: Epub Date]].
- 11 21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics
12 1977;**33**(1):159-74
- 13 22. Emanuel EJ, Wendler D, Killen J, et al. What makes clinical research in developing countries
14 ethical? The benchmarks of ethical research. The Journal of infectious diseases
15 2004;**189**(5):930-7 doi: 10.1086/381709[published Online First: Epub Date]].
- 16 23. Karanja S, Mbuagbaw L, Ritvo P, et al. A workshop report on HIV mHealth synergy and
17 strategy meeting to review emerging evidence-based mHealth interventions and develop
18 a framework for scale-up of these interventions. The Pan African medical journal
19 2011;**10**:37
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. PubMed search strategy, modified as needed for use in other databases

Search	PubMed
#1	(immunization[Mesh]) OR (immunis* OR immuniz* OR vaccin*)
#2	(adolescents OR children OR teenagers)
#3	"SMS" OR cellphone OR "mobile phone" OR "text messaging" OR "short message service" OR "text reminder"
#4	#1 AND #2
#5	#3 AND #4

MeSH, medical subject heading

1
2
3
4
5
6
7 Mobile phone text messaging for improving the uptake of vaccinations: a systematic
8 review protocol
9

10
11 Robyn Kalan

12 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
13 Road, Observatory 7925, Cape Town, South Africa
14
15 Robyn.kalan@gmail.com
16

17
18
19 Charles S. Wiysonge

20 Department of Interdisciplinary Health Sciences, Faculty of Medicine and Health
21 Sciences, Stellenbosch University, Tygerberg 7505, Cape Town, South Africa
22
23 charlesw@sun.ac.za
24

25
26 Tshepiso Ramafuthole

27 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
28 Cape Town, South Africa
29
30 rmftsh001@myuct.ac.za
31

32
33 Kurt Allie

34 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
35 Cape Town, South Africa
36
37 allkur003@myuct.ac.za
38

39
40 Fatima Ebrahim

41 Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925,
42 Cape Town, South Africa
43
44 ebrfat010@myuct.ac.za
45

46
47
48 Mark Emmanuel Engel

49 Department of Medicine, Faculty of Health Sciences, University of Cape Town, Anzio
50 Road, Observatory 7925, Cape Town, South Africa
51
52 mark.engel@uct.ac.za
53

1
2
3
4
5
6
7
8 ***Corresponding author**

9 Dr Mark Emmanuel Engel

10 Department of Medicine, University of Cape Town

11 J46-43, Old Main Building, Groote Schuur Hospital

12 Anzio Road, Observatory 7925, South Africa

13 Phone: +27 21 404 7676

14 Fax: 27 21 448 6815

15 E: mark.engel@uct.ac.za
16
17
18
19
20
21
22
23
24
25

26 **Keywords:** Vaccine coverage, vaccination, Mobile text messaging, short messaging
27 service, SMS
28
29
30
31
32
33
34
35

36 **Word Count:** 2424
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Background/Introduction: Low vaccine coverage is a major public health concern, the consequences of which contribute to around 1.5 million child deaths from vaccine-preventable diseases. Thus, innovative strategies to rapidly increase coverage and recall rates for vaccinations are urgently required. Mobile text messaging (or short messaging service, SMS) has the potential to help increase vaccination coverage and therefore we propose to conduct a review of the current best evidence for the use of SMS as an intervention to promote vaccination coverage.

Methods and Analysis/Design: This article describes the protocol for a systematic review of the effectiveness of SMS in improving the uptake of vaccination. Primary and secondary outcomes of interest are pre-specified. We will preferably include randomized controlled trials (RCTs). However, non-randomized studies (NRS) will be considered if there is an inadequate number of RCTs. We will search several bibliographic databases (for example PubMed, EMBASE, CINAHL, CENTRAL, Science Citation Index, Africa-Wide Information, and WHOLIS electronic databases and search sources for grey literature. Following data extraction and assessment of risk of bias, we will meta-analyze studies and conduct sub-group analyses, according to intervention subtypes. We will assess clinical heterogeneity and statistical heterogeneity. For outcomes without quantitative data, a descriptive analysis will be used. [This review protocol is registered in the PROSPERO International Prospective Register of systematic reviews, registration number 2014:CRD42014007531](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DiscussionEthics and dissemination: Ethics is not required for this study, given that this is a protocol for a systematic review, which uses published data. This findings of this study will be disseminated through peer-reviewed publications and conference presentations. We anticipate that the Our results could ~~can~~ be used by researchers and policy-makers to help inform them of the efficacy of mobile phone text messaging interventions to promote increased vaccination coverage.

Strengths and limitations of this study

- To our knowledge, this is the first systematic review protocol that will attempt to assess the impact of mobile text messaging on promoting the uptake of vaccination amongst adults, adolescents and parents or caregivers of children.
- This study will help inform clinical practice and future studies on the effectiveness of media platforms.
- Non-randomised studies of low-quality evidence may be this study's limitation. We will, however, conduct appropriate analyses to assess the overall robustness of the results.

BackgroundIntroduction

Vaccinations, when given at the most sensitive developmental years of childhood, help to promote comprehensive and capable immunity, enabling children to fight off certain diseases [1 2]. In addition, vaccinations are widely regarded as one of the most cost-effective public health interventions that help to reduce global child morbidity and mortality [3 4]. Low coverage of vaccinations is a major public health concern. In Africa alone, more than seven million children did not receive the full spectrum of vaccinations recommended before reaching one year of age in 2009 [5]. It is also estimated that 1.5 million children died globally from vaccine-preventable diseases where World Health Organization (WHO) pre-qualified vaccines were available [6].

The Global Vaccine Action plan (GVAP) is the most recently launched global effort by the WHO to help increase vaccination coverage. The GVAP has set a target that by 2020 vaccination coverage for populations should reach 90% national vaccination coverage and at least 80% at district levels utilizing national vaccination programmes [7]. It is guided by six principles: country ownership, shared responsibility and partnership, equity, integration, sustainability, and innovation [8]

A variety of factors impact achieving low coverage rates; challenges such as immunisation awareness, demand for immunisation, level of trust in the health system, adequate human resources, access, timeliness of vaccinations, service delivery, poor infrastructure and vaccination monitoring [4]. Vaccination coverage seems to be lower in low-income households, where limited access to health education, contributes to poor

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

health-seeking behaviour along with an inability to improve general wellbeing [1 2 9]. Uneducated parents therefore are less likely to understand the importance of vaccinating to prevent potentially harmful diseases. In light of these obstacles to vaccination coverage, the strategy to improve vaccination coverage needs to be innovative as alluded to in the GVAP, well thought out and able to penetrate low income households effectively.

Globally, mobile phone use is rapidly increasing, with an estimated six billion mobile phone users worldwide at the end of 2011 [10]. In particular, mobile phone text messaging has gained popularity among people living in low- and middle-income countries and may be the key to penetrating hard to reach areas in the developing world. Text messaging has proven to be a cost effective method of relaying health information and reminders than the more traditional methods such as face-to-face, phone calls, pamphlets, mail and email [5]. As immunisation usually requires multiple consecutive monthly visits after the first vaccine dose in order to complete the schedule, short messaging service (SMS) can be used as reminder for an upcoming visit and recall when a visit has been missed [1]. In addition, an SMS intervention, also known as mobile phone text messaging, can be delivered alone or bundled with other interventions [11]. Diseases that have used mobile technology successfully include HIV where a 90% adherence was observed among text message recipients compared with a 40% adherence in the control group [12]. We therefore propose to conduct a systematic review of the current best evidence for the use of mobile phone text messaging to improve vaccination coverage.

Methods

This review protocol has been published in the PROSPERO International Prospective Register of systematic reviews (<http://www.crd.york.ac.uk/PROSPERO>), registration number 2014:CRD42014007531.

Criteria for considering studies for this review

Type of studies

We will include randomized controlled trials (RCTs), interrupted time series and controlled before and after studies (CBA).

Types of participants

Participants will be caregivers of infants or children, adolescents and adults including pregnant women drawn from any setting, community-based or otherwise.

~~Participants will be adults, children or caregivers of those receiving vaccinations, in community-based settings.~~

Types of interventions

We will include interventions in which mobile phone text messages serve as a reminder to be vaccinated, as educational information or, as information regarding vaccine availability at the clinic in an attempt ~~are used~~ to promote uptake of vaccinations. Vaccinations could include routine infant immunisations, those against human papilloma virus, influenza, meningococcal (MCV4) or tetanus/diphtheria/acellular pertussis (Tdap). ~~The text messaging needs to be delivered to a person needing a vaccination, or in the case of an infant or~~

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~child, to a caregiver.~~ Eligible studies will be those that compared SMS to no intervention, or to other interventions for increasing vaccination coverage. If we find less than ten studies that include only SMS as the intervention, we will include studies in which mobile phone voice speaking or voice messaging are interventions; studies in which the use of a beeper or pager is the intervention; studies in which the use of multimedia messaging service is the intervention; and studies in which text messages are bundled with other interventions. In such circumstances, we will stratify the analysis by type of intervention.

Types of outcome measures

Results must include quantitative data for outcomes measured.

Primary outcomes:

The primary outcome is vaccination coverage, irrespective of disease. We will use the definition of vaccine coverage as stipulated by the respective authors.

Secondary outcomes:

Secondary outcomes are the recall rate in persons who had previously missed their vaccinations. scheduled appointments for vaccination or completeness of vaccination records.

Search methods for identification of studies

A comprehensive and exhaustive search of databases and conference proceedings will be performed by RK with the help of the University of Cape Town librarian, to identify all relevant studies available by ~~30 June 2013~~30 June 2014, regardless of language or

1
2
3
4
5
6
7 publication status. We will search both peer-reviewed journal articles and grey
8 literature (unpublished, internal or non-reviewed papers and reports).
9

10 11 12 **Database**

13
14
15 We will search the following electronic databases: PubMed; EMBASE; Cochrane Central
16 Register of Controlled Trials (CENTRAL); ISI Web of Science (Science Citation Index);
17 Africa-Wide Information, Cumulative Index of Nursing and Allied Health (CINAHL), and
18 WHO library databases (WHOLIS). We will use both text words and medical subject
19 heading (MeSH) terms; for example vaccination*, immunization*, immunisation*,
20 "Immunization"(MeSH), "Vaccination"(MeSH), "Immunization, Secondary"(MeSH) OR
21 "Immunization Programs"(MeSH), "Immunization Schedule"(MeSH), "Mass
22 Vaccination"(MeSH), mobile phone, text messaging, text*, SMS, reminder*, recall,
23 telemedicine, mHealth, and eHealth. These terms will be used in varying combinations.
24
25 The literature search strategy will be adapted to suit each database. Table 1 shows the
26 main search strategy we will use.
27
28
29
30
31
32
33
34
35
36
37

38 **Conference proceedings**

39
40 We will search the following conference proceedings for relevant abstracts: Vaccine and
41 International Society for Vaccines Congress, International African Vaccinology Conference,
42 Annual Vaccines Congress, Annual Conference on Vaccine Research, World Congress on
43 Pediatric Infectious Diseases, International Pediatric Association Conference, National
44 Immunization Conference, and the Annual Infectious Diseases in Children Symposium.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Searching other sources

For ongoing studies, we will search the WHO International Clinical trials Registry Platform, Clinicaltrials.gov, Pan African Clinical Trials Registry (PACTR), and contact individual researchers working in the field as well as the following organizations: WHO, Global Alliance for Vaccines and Immunisation, Centers for Disease Control and Prevention, and mHealth Alliance. We will also search the website of mHealth Alliance and mHealth in the Low Resource Settings resources database for eligible studies.

Reference lists

We will obtain reference lists of relevant studies identified and the full-text articles reviewed for inclusion in the review will be checked for additional information.

Data collection and analysis

The methods for data collection and analysis will be based on the Cochrane Handbook of Systematic Reviews for Interventions [13].

Selection of studies for inclusion

We will construct a screening guide to ensure that the inclusion criteria are adhered to and consistently applied by all review authors. Two review authors (RK and ME), working independently, will screen the titles and abstracts of all studies identified through the literature searches for eligibility. RK will obtain the full text of studies deemed potentially eligible. The two authors (RK and ME) will independently assess the full text of each article for eligibility, and compare their results and resolve

1
2
3
4
5
6
7 discrepancies by discussion and consensus, consulting a third author (CW) to resolve
8
9 any persistent disagreements. For all studies excluded by the assessors we will describe
10
11 the reasons for exclusion.

~~Data extraction and management~~

~~References will be managed using Thomson ISI Research Soft Endnote 9.0 [14]. Two
17
18 authors will independently extract descriptive and outcome data for each included
19
20 article using a standardized data collection form, resolving any discrepancies by
21
22 discussion and consensus; failing which, a third author (CW) will arbitrate. RK will
23
24 enter the final data into the Cochrane Collaboration Review Manager Version 5.1
25
26 statistical software (<http://ims.cochrane.org/RevMan>). CW will crosscheck the data
27
28 entered to ensure that there are no data entry errors.~~

Assessment of risk of bias in included studies

32
33 Two authors will independently assess the risk of bias in the included studies. Separate
34
35 criteria will be used to assess RCTs and non-randomized studies. The criteria used to
36
37 assess the risk of bias of in RCTs will be random sequence generation; allocation
38
39 concealment; blinding of participants, study personnel; blinding of outcome assessors;
40
41 incomplete outcome data; selective outcome reporting; other sources of bias, and
42
43 overall risk of bias, in accordance with the methods used by the Cochrane Collaboration
44
45 [13] as well as the Cochrane Consumers and Communication Review Group[15]. The
46
47 criteria used for risk of bias assessment for non-randomized studies will include
48
49 selection bias (with regard to comparability of groups, confounding and adjustment);
50
51 performance bias (in terms of the fidelity of the interventions, and quality of the
52
53 information regarding who received which interventions, including blinding of study
54
55
56
57
58
59
60

1
2
3
4
5
6
7 subjects and healthcare providers); detection bias (regarding unbiased and correct
8 assessment of outcomes, including blinding of assessors); attrition bias (with regard to
9 completeness of sample, follow-up and data); and reporting bias (with regard to
10 publication biases and selective reporting of results) [13]. Studies will be scored as
11 having low, high or unclear risk of bias. The two authors will resolve disagreements in
12 the assessment of risk of bias by discussion and consensus, consulting a third author to
13 resolve any persistent disagreements.
14
15
16
17
18
19

Data extraction and management

20
21
22 References will be managed using Thomson ISI Research-Soft Endnote 9.0 [14]. Two
23 authors will independently extract descriptive and outcome data for each included
24 article using a standardized data collection form, resolving any discrepancies by
25 discussion and consensus; failing which, a third author (CW) will arbitrate. RK will
26 enter the final data into the Cochrane Collaboration Review Manager Version 5.1
27 statistical software (<http://ims.cochrane.org/RevMan>). CW will crosscheck the data
28 entered to ensure that there are no data entry errors.
29
30
31
32
33
34
35
36
37
38
39
40

Data synthesis including assessment of heterogeneity

Measures of treatment effect

41
42
43
44
45
46 Data analysis will be conducted using the Cochrane Collaboration Review Manager
47 Version 5.1 statistical software (<http://ims.cochrane.org/RevMan>). The outcomes of
48 interest will be either dichotomous or continuous. We will calculate risk ratios and their
49 corresponding 95% confidence intervals and P-values for dichotomous outcomes, and
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 mean differences and standard deviations for continuous outcomes. Where outcomes are
8 measured using different scales, we will report standardised mean differences (SMD) [16].

Formatted: Font: (Default) Times New Roman

12 ***Dealing with missing data***

13
14
15 In cases of missing or incomplete information presented in the included studies, we shall
16 contact authors for further information.

20 ***Data synthesis, assessment/investigation of heterogeneity***

21
22
23 We will assess clinical heterogeneity by examining types of participants, interventions,
24 and outcomes in each study. We will pool data only from studies judged to be clinically
25 homogenous. Statistical heterogeneity in each meta-analysis will be assessed using the
26 chi-square test and quantified using the I-squared statistic [17] . If studies are
27 sufficiently homogenous (in terms of study populations, interventions, and outcomes),
28 then we will pool the data across studies and estimate summary effect sizes using a
29 fixed-effects model. Otherwise, we will use the random-effects model. Should
30 heterogeneity remain significant, we will discuss the findings as a narrative summary.

31
32
33 We will perform subgroup analyses by intervention subtypes: long versus short
34 messages; daily versus weekly messages; short weekly messages versus long weekly
35 messages; short daily messages versus long daily messages; and two-way interactive
36 communication versus one-way communication [12 18 19]. We will also stratify analysis
37 by study design (randomized controlled separate from non-randomized studies) and
38 intervention type (multiple interventions involving text messaging separate from text
39 messaging alone). We will also conduct a subgroup comparison of self-reported vaccination
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 completion versus verified clinic records as well as according to age categories and country
8 setting.
9

10
11
12 Finally, we will use the grading of recommendations assessment, development, and
13 evaluation (GRADE) approach [20] to assess the quality of evidence for the effectiveness
14 of the SMS intervention. This method results in an assessment of the quality of the body
15 of evidence as high, moderate, low, or very low. Evidence is considered of high quality if
16 'further research is very unlikely to change our confidence in the estimate of effect'; and
17 moderate quality if 'further research is likely to have an important impact on our
18 confidence in the estimate of effect and may change the estimate'. Low quality evidence
19 implies that 'further research is very likely to have an important impact on our
20 confidence in the estimate of effect and is likely to change the estimate', and very low
21 quality that 'we have very little confidence in the effect estimate'.
22
23
24
25
26
27
28
29
30
31
32
33
34

35 ***Sensitivity analyses***

36
37 Several sensitivity analyses will be performed: first to determine whether the study
38 design (RCT versus nonrandomized study) could influence the results of the meta-
39 analysis; second, to evaluate whether the model of the statistical method (random-
40 effects vs fixed-effects model) could change the results, and third, to determine the
41 impact of excluding studies with a high risk bias on the results, with emphasis on
42 allocation concealment, blinded outcome assessment, and losses to follow-up (with a cut
43 off of 25% loss to follow-up).
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Presenting and reporting of results this review

Findings in our systematic review will be presented in several ways. Flow diagrams will be used to summarise the study selection process. Funnel plots will be used to assess publication bias if we identify 10 or more eligible studies. The kappa statistic [21] will be used to assess agreements between the full-text screening, data extraction and risk of bias assessment by the two authors (RK and ME). GRADE summary of tables of findings, risk of bias tables or graphs, and forest plots will also be used where appropriate. The reporting of outcomes without quantitative data will be descriptive. Lastly, we will provide a list of excluded studies with reasons for exclusion.

Ethics and dissemination

Systematic reviews draw on publicly available data and do not directly involve human subjects, and therefore do not require formal ethical review [22]. The study protocol will be reviewed by supervisors with expertise in methodology (systematic review) and submitted to the University of Cape Town Departmental Research Committee for approval.

Formatted: Justified, Space Before: 6 pt, After: 10 pt, Don't add space between paragraphs of the same style, Line spacing: Double

Discussion

Expected significance of the study

The findings of this systematic review will have implications for policy, practice and research. We will discuss the relevance of our findings to childhood immunisation programmes in Africa in the decade of vaccines with emphasis on applicability, effects on equity, cost implications, and monitoring and evaluation. Our systematic review will provide evidence of whether policy-makers can adopt mobile phone text messaging alone or in combination with other interventions in efforts to improve uptake of vaccines in national immunisation programmes. It will also inform clinic or hospital managers of how best to use the intervention to improve vaccination coverage. The systematic review may also identify specific considerations that would need to be taken into account for future studies, such as study location, content and timing of messages, whether or not parents or caregivers replied to text messages, how text messages were sent (automated versus manual), indicators for immunisation programmes, variety of text messages sent (inclusion of jokes or lifestyle tips), duration of the study, whether or not participants were provided with the mobile handsets, and sample size [23].

Abbreviations

WHO: World Health Organization; GVAP: Global Vaccine Action plan; SMS: Short messaging service; RCT: Randomized Controlled Trials; CBA: Controlled Before and After study; MeSH: medical subject heading;

Formatted: Space After: 10 pt, Line spacing: Multiple 1.15 li, Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

Formatted: Justified, Space Before: 6 pt, Don't add space between paragraphs of the same style, Line spacing: Double, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

Acknowledgements

The authors would like to acknowledge the critical input and support of the Evidence-Based Medicine Research Support Unit, Faculty of Health Sciences, University of Cape Town.

Author's eContributionship statement

Robyn Kalan, BSc (Hons) Nursing is a research fellow. Tshepiso Ramafuthole, Kurt Allie and Fatima Ebrahim are MBChB students. Mark Engel, MPH, PhD and Charles Wiysonge, MD, PhD are senior researchers.

CW, TR, KA, and FE conceived of the review. All authors developed the design of the protocol and will be involved in data acquisition. RK undertook the drafting of the manuscript. RK and ME will analyze the data and participate in the interpretation of the results. All authors have given their approval for publication.

Competing interests

The authors declare that they have no competing interests.

Funding

We did not receive any dedicated funding for this manuscript.

References

1. Garde M. Inequalities in child survival: Looking at wealth and other socio-economic disparities in developing countries.
http://www.savethechildren.org.uk/sites/default/files/docs/Final_draft_inequalities_of_child_survival_10_August_formatted_2_1.pdf [Accessed August 5th 2012] 2010
2. Multiple Authors. Vaccines & Preventable Diseases. National Center for Immunization and Respiratory Disease. <http://www.cdc.gov/vaccines/vpd-vac/default.htm> 2009
3. Bloom DE. The value of vaccination. *Advances in experimental medicine and biology* 2011;**697**:1-8 doi: 10.1007/978-1-4419-7185-2_1 [published Online First: Epub Date]].
4. Machingaidze S, Wiysonge CS, Hussey GD. Strengthening the expanded programme on immunization in Africa: looking beyond 2015. *PLoS medicine* 2013;**10**(3):e1001405 doi: 10.1371/journal.pmed.1001405 [published Online First: Epub Date]].
5. Stockwell MS, Kharbanda EO, Martinez RA, et al. Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations. *American journal of public health* 2012;**102**(2):e15-21 doi: 10.2105/AJPH.2011.300331 [published Online First: Epub Date]].
6. World Health Organisation and UNICEF: Global Immunization Data. World Health Organisation and UNICEF: Global Immunization Data.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
7. WHO Global Vaccination Action Plan.
[http://www.who.int/immunization_monitoring/Global_Immunization_Data.pdf]
Accessed 10 June 2013
8. Decade of Vaccines (DoV) Collaboration: Draft global vaccine action plan.
[<http://www.dovcollaboration.org/action-plan/>] Accessed 10 June 2013
9. Kaewkungwal J, Singhasivanon P, Khamsiriwatchara A, et al. Application of smart phone in "Better Border Healthcare Program": a module for mother and child care. *BMC medical informatics and decision making* 2010;**10**:69 doi: 10.1186/1472-6947-10-69 [published Online First: Epub Date]].
10. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. *Medical care* 1998;**36**(8):1138-61
11. Mohammed S, Siddiqi O, Ali O, et al. User engagement with and attitudes towards an interactive SMS reminder system for patients with tuberculosis. *J Telemed Telecare* 2012;**18**(7):404-8 doi: 10.1258/jtt.2012.120311 [published Online First: Epub Date]].

12. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS* 2011;**25**(6):825-34 doi: 10.1097/QAD.0b013e32834380c1[published Online First: Epub Date]].
13. Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from <http://www.cochrane-handbook.org>, 2009.*
14. Thomson. <http://www.endnote.com>. ISI Research-Soft Endnote 90
15. Ryan R HS, Prictor M, McKenzie J. Cochrane Consumers and Communication Review Group. Study Quality Guide. http://ccrgcochraneorg/sites/ccrgcochraneorg/files/uploads/StudyQualityGuide_May2011pdf (accessed 01 February 2013) 2011
16. Borenstein M. *Introduction to meta-analysis*. Chichester, U.K.: John Wiley & Sons, 2009.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;**21**(11):1539-58
18. Horvath T, Azman H, Kennedy GE, et al. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. *Cochrane Database Syst Rev* 2012;**3**:CD009756 doi: 10.1002/14651858.CD009756[published Online First: Epub Date]].
19. Thirumurthy H, Lester RT. M-health for health behaviour change in resource-limited settings: applications to HIV care and beyond. *Bulletin of the World Health Organization* 2012;**90**(5):390-2 doi: 10.2471/BLT.11.099317[published Online First: Epub Date]].
20. Balslem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011;**64**(4):401-6 doi: 10.1016/j.jclinepi.2010.07.015[published Online First: Epub Date]].
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;**33**(1):159-74
22. Emanuel EJ, Wendler D, Killen J, et al. What makes clinical research in developing countries ethical? The benchmarks of ethical research. *The Journal of infectious diseases* 2004;**189**(5):930-7 doi: 10.1086/381709[published Online First: Epub Date]].
23. Karanja S, Mbuagbaw L, Ritvo P, et al. A workshop report on HIV mHealth synergy and strategy meeting to review emerging evidence-based mHealth interventions and develop a framework for scale-up of these interventions. *The Pan African medical journal* 2011;**10**:37

Table 1. PubMed search strategy, modified as needed for use in other databases

Search	PubMed
#1	(immunization[Mesh]) OR ((immunis* OR immuniz* OR vaccin*)
#2	(adolescents OR children OR teenagers)
#3	"SMS" OR cellphone OR "mobile phone" OR "text messaging" OR "short message service" OR "text reminder"
#4	#1 AND #2
#5	#3 AND #4

MeSH, medical subject heading